Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 3Recurrence 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Nephrotic Syndrome 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Bladder Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Depression 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1Anxiety Disorders 1

Interventions

Cisplatin 90Fluorouracil 76Radiotherapy 63Paclitaxel 58Docetaxel 49Oxaliplatin 48Irinotecan 42Leucovorin 32Capecitabine 31Carboplatin 27Radiation 21Surgical Procedures, Operative 20Esophagectomy 20pembrolizumab 15Neoadjuvant Therapy 15Bevacizumab 15Cetuximab 13Drug Therapy 12Epirubicin 11Chemotherapy, Adjuvant 9S 1 (combination) 8Magnetic Resonance Spectroscopy 8Gemcitabine 8Trastuzumab 7Nivolumab 7Erlotinib Hydrochloride 7Surveys and Questionnaires 6Panitumumab 6Immunohistochemistry 6Chemoradiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Neoplasms × Pharmaceutical Preparations × Clear all
NCT00318903 2023-05-25

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

University of Alabama at Birmingham

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡